Subsidiary YKYY018 of Youcare Pharmaceutical Group (688658.SH) approved for clinical trials of aerosol inhalation therapy for the treatment and prevention of human parainfluenza virus infection.

18:20 02/04/2026

Yuekang Pharmaceuticals (688658.SH) announced that its wholly-owned subsidiary, Beijing Yuekang Innovation Pharmaceutical Technology Co., Ltd. (referred to as "Yuekang Innovation"), recently received two "Drug Clinical Trial Approval Notices" from the National Medical Products Administration (NMPA) for the approval of YKYY018 nebulized inhalation agents for the treatment and prevention of human paraflu virus.

Youcare Pharmaceutical Group (688658.SH) announced that its wholly-owned subsidiary, Beijing Yuet Kangkechuang Pharmaceutical Technology Co., Ltd. (known as "Yukang Technology"), recently obtained two Drug Clinical Trial Approval Notices from the National Medical Products Administration (NMPA) approving the use of YKYY018 nebulized inhalation solution for the treatment and prevention of human metapneumovirus. After the launch of YKYY018 nebulized inhalation solution, it will effectively address the treatment challenges of current respiratory syncytial virus infections and human metapneumovirus infections, fill the clinical treatment field gap, and have significant clinical value, social benefits, and economic benefits.

China Galaxy Securities: High oil prices fluctuate, focus on alternative routes for oil.

Sinolink: Collaborative computing included in national strategy, multi-industry resonance on the same frequency.

Energy crisis does not hinder the expansion ambition: Microsoft Corporation (MSFT.US) increases investment in Japan by $10 billion, joining forces with SoftBank and Sakura to build AI cloud infrastructure.

China Galaxy Securities: High oil prices fluctuate, focus on alternative routes for oil.

Sinolink: Collaborative computing included in national strategy, multi-industry resonance on the same frequency.